Immunovant, Inc. IMVT
We take great care to ensure that the data presented and summarized in this overview for Immunovant, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding IMVT
View all-
Vanguard Group Inc Valley Forge, PA6.68MShares$184 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT6MShares$165 Million7.27% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD5.12MShares$141 Million0.08% of portfolio
-
Black Rock Inc. New York, NY4.92MShares$135 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY3.87MShares$106 Million1.5% of portfolio
-
State Street Corp Boston, MA2.7MShares$74.2 Million0.0% of portfolio
-
Alpine Global Management, LLC New York, NY2.16MShares$59.4 Million22.44% of portfolio
-
Perceptive Advisors LLC New York, NY2.14MShares$58.8 Million1.96% of portfolio
-
Baker Bros. Advisors LP New York, NY1.71MShares$47 Million0.52% of portfolio
-
Geode Capital Management, LLC Boston, MA1.52MShares$41.7 Million0.0% of portfolio
Latest Institutional Activity in IMVT
Top Purchases
Top Sells
About IMVT
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Insider Transactions at IMVT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 19
2025
|
Eva Renee Barnett Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,814
-0.87%
|
$56,280
$20.86 P/Share
|
|
Feb 19
2025
|
William L. Macias Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,055
-0.57%
|
$41,100
$20.86 P/Share
|
|
Feb 19
2025
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,439
-1.6%
|
$308,780
$20.86 P/Share
|
|
Jan 22
2025
|
Michael Geffner Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,657
-1.97%
|
$61,111
$23.59 P/Share
|
|
Jan 22
2025
|
Jay S Stout Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
2,195
-1.54%
|
$50,485
$23.59 P/Share
|
|
Jan 15
2025
|
Eva Renee Barnett Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,298
-0.35%
|
$55,152
$24.0 P/Share
|
|
Jan 15
2025
|
William L. Macias Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,383
-0.16%
|
$57,192
$24.0 P/Share
|
|
Jan 15
2025
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
8,767
-0.45%
|
$210,408
$24.0 P/Share
|
|
Jan 13
2025
|
Roivant Sciences Ltd. |
BUY
Open market or private purchase
|
Direct |
16,845,010
+14.84%
|
$336,900,200
$20.0 P/Share
|
|
Jan 08
2025
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,105
-0.52%
|
$122,520
$24.1 P/Share
|
|
Jan 08
2025
|
Eva Renee Barnett Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,105
-1.24%
|
$98,520
$24.1 P/Share
|
|
Dec 16
2024
|
Christopher Van Tuyl Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
109,956
+50.0%
|
-
|
|
Dec 02
2024
|
Douglas J. Hughes Director |
SELL
Open market or private sale
|
Direct |
5,425
-4.34%
|
$151,900
$28.54 P/Share
|
|
Dec 02
2024
|
Atul Pande Director |
SELL
Open market or private sale
|
Direct |
7,750
-8.21%
|
$217,000
$28.54 P/Share
|
|
Nov 20
2024
|
Eva Renee Barnett Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,174
-1.24%
|
$104,350
$25.45 P/Share
|
|
Nov 20
2024
|
William L. Macias Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,353
-0.92%
|
$83,825
$25.45 P/Share
|
|
Nov 20
2024
|
Mark S. Levine Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,650
-1.13%
|
$91,250
$25.45 P/Share
|
|
Nov 20
2024
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
16,692
-1.68%
|
$417,300
$25.45 P/Share
|
|
Nov 18
2024
|
Melanie Gloria Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
109,956
+50.0%
|
-
|
|
Oct 23
2024
|
Mark S. Levine Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
4,361
-1.33%
|
$126,469
$29.53 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 876K shares |
|---|---|
| Open market or private purchase | 16.8M shares |
| Open market or private sale | 325K shares |
|---|